SI-BONE Holds Its Revenue Forecast, Trims Spending Plan After U.S. Procedures Grow About 19.5%
The spinal-implant maker cut its third-quarter net loss to $3.6 million and turned cash from operations positive at $5.9 million.
SI-BONE, which makes titanium implants for sacroiliac joint dysfunction, a source of lower back pain, said U.S. procedure volume grew about 19.5% in the third quarter and worldwide revenue rose 14.5% to $55.7 million, according to an 8-K filed Monday. The company kept its 2026 revenue guidance and lowered how fast it expects operating expenses to grow.
Volume up, price per procedure down
U.S. revenue reached $52.8 million, up 13.9% from $46.4 million a year earlier, the company reported. Procedure growth of about 19.5% was partly offset by a lower average selling price, which the company tied to procedure mix and rising demand from interventional spine physicians for its INTRA platform in office-based and ambulatory surgery settings.
International revenue rose 27.0% to $2.9 million from $2.3 million, which the company linked to adoption of iFuse TORQ and iFuse TORQ TNT. Gross margin was 79.3%, versus 79.8% a year earlier.
Active U.S. physicians numbered 1,770, up about 16% from a year earlier.
A narrower loss and positive cash flow
The net loss narrowed 20.7% to $3.6 million, or $0.08 per share, from $4.6 million, or $0.11, a year ago. Operating expenses rose 9.7% to $48.5 million, driven by sales commissions, marketing for new products and research spending.
Adjusted EBITDA, which strips out interest, depreciation and stock pay, was positive $3.0 million versus $2.3 million. Cash from operations was positive $5.9 million, and cash and equivalents ended September at $146.3 million, up from $145.9 million at June 30.
For the first nine months, free cash flow was negative $4.6 million, against negative $9.5 million a year earlier.
Guidance and the product pipeline
Revenue guidance stays at $231 million to $233 million, as does the roughly 79.0% gross margin target. Based on spending so far this year, SI-BONE now expects operating expenses to grow about 10.5% at the revenue midpoint, down from about 12.0% in its August outlook.
In September the company received FDA 510(k) clearance for iFuse Granite Onyx, which targets failures in spine fusion procedures and carries an estimated addressable market of about $1.5 billion a year. In October, new payment categories took effect for complex spinal fusions using iFuse Bedrock Granite, lifting average hospital inpatient payments by up to about $50,000 per qualifying procedure.
CEO Laura Francis said the company enters the fourth quarter with "a record number of active physicians" and "exceptional early uptake" in the alpha launch of iFuse Granite Onyx.
Management discussed the results on a call at 4:30 p.m. ET Monday, after the market closed.